Abstract
Excessive solar ultraviolet (SUV) radiation often causes dermatitis, photoaging, and even skin cancer. In the pathological processes of SUV-induced sunburn, JNK is activated by phosphorylation, and it in turn phosphorylates its downstream transcription factors, such as ATF2 and c-jun. The transcription factors further regulate the expression of pro-inflammatory genes, such as IL-6 and TNF-α, which ultimately leads to dermatitis. Therefore, inhibiting JNK may be a strategy to prevent dermatitis. In this study, we screened for worenine as a potential drug candidate for inhibiting sunburn. We determined that worenine inhibited the JNK-ATF2/c-jun signaling pathway and the secretion of IL-6 and TNF-α in cell culture and in vivo, confirming the role of worenine in inhibiting sunburn. Furthermore, we determined that worenine bound and inhibited JNK2 activity in vitro through the MST, kinase, and in vitro kinase assays. Therefore, worenine might be a promising drug candidate for the prevention and treatment of SUV-induced sunburn.
Introduction
Solar ultraviolet (SUV) radiation is a primary environmental driver of skin damage, leading to acute conditions like sunburn (dermatitis) and chronic issues such as premature aging and skin cancer. At the molecular level, SUV exposure triggers a stress response in skin cells that activates the c-Jun N-terminal kinase (JNK) signaling pathway. Once activated, JNK phosphorylates transcription factors like ATF2 and c-jun, which then enter the nucleus to trigger the production of pro-inflammatory cytokines, including IL-6 and TNF-α. This inflammatory cascade is responsible for the clinical symptoms of sunburn. While sunscreens provide a physical or chemical barrier, there is a significant need for pharmacological agents that can intervene in these biological pathways.
Methodology
Researchers employed a multi-tiered experimental approach to identify and validate potential inhibitors:
- Screening: Eight compounds from Traditional Chinese Medicine (TCM), including worenine (derived from Coptis chinensis), were screened for their ability to inhibit SUV-induced signaling.
- In Vitro Analysis: Human keratinocytes (HaCaT) and mouse skin cells (JB6 Cl41) were used to assess cell viability and the phosphorylation of JNK, ATF2, and c-jun via Western Blotting.
- Biochemical Assays: Microscale Thermophoresis (MST) measured the binding affinity ($K_D$) between worenine and JNK2. In vitro kinase assays were used to determine if worenine could physically block JNK2 activity.
- In Vivo Validation: Balb/c mice were treated with a topical worenine cream before SUV exposure. Histological analysis (H&E staining) measured epidermal thickness, and ELISA assays quantified inflammatory cytokine levels.
Key Results and Discussion
The study identified worenine (WOR) as the most potent inhibitor among the screened TCM compounds for blocking the SUV-induced JNK signaling pathway.
Signaling and Inflammatory Inhibition
Worenine significantly suppressed the phosphorylation of JNK, ATF2, and c-jun in a dose- and time-dependent manner. This molecular inhibition led to a marked decrease in the secretion of IL-6 and TNF-α. Biochemical assays confirmed that worenine directly binds to JNK2 with a dissociation constant ($K_D$) of 116.4 μM. Furthermore, 12.5 μM of worenine inhibited JNK2 activity by approximately 22%, outperforming its effects on other kinases like Src or Met.
Physical and Biological Protection
In the mouse model, SUV exposure typically causes significant epidermal thickening as a sign of damage. However, mice treated with worenine (21 μg/cm²) exhibited much thinner, healthier epidermal layers, comparable to those treated with the positive control, paeonol. Notably, this effective dose is significantly lower than the international standard for sunscreen application (2 mg/cm²), suggesting high potency. The researchers hypothesize that worenine may offer dual protection: its chemical structure allows it to absorb some UV radiation, while its molecular shape enables it to act as a targeted kinase inhibitor.
Conclusion and Future Directions
Worenine is a promising drug candidate for the prevention of SUV-induced sunburn due to its specific inhibition of JNK2. However, some discrepancies were noted; for instance, total JNK levels decreased in vitro but not in vivo, suggesting worenine might trigger JNK degradation via the autophagy-lysosome pathway in specific contexts. Future research is needed to determine if worenine can act as a "rescue" treatment after exposure and to validate these findings in human clinical trials.
Summary updated